Piper remains buyer of MAKO shares following Q4 results Piper Jaffray says MAKO Surgical's 2013 outlook indicates 29%-31% growth in the company’s robot installed base with procedure growth of 35%-40%. Piper thinks investors can again believe in the company's growth story and reiterates an Overweight rating on the stock with a $23 price target. The firm said it remains a buyer of MAKO shares following the company’s Q4 results.
News For MAKO From The Last 14 Days
Check below for free stories on MAKO the last two weeks.